Aromatase inhibitor cuts risk of recurrence of breast cancer

Switching postmenopausal women with breast cancer to the aromatase inhibitor exemestane after two to three years of treatment with tamoxifen keeps them free of disease for longer than treating them with tamoxifen alone, suggests an interim analysis of trial data. After a median of 30 months follow up, it made little difference to survival, however.

The authors conclude that standard adjuvant treatment with five years of tamoxifen may no …